M.D., Founder & CEO, Navidence
Biography
Dr. Aaron Kamauu is an industry-leading advisor in the Real-World Data (RWD) space, specifically focusing on leveraging real-world healthcare data to support a variety of clinical research, informatics, clinical trials, and drug development activities, including pharmacoepidemiology, outcomes research, protocol design, site identification, data-driven patient recruitment, and the use of RWD to support evidence generation & submission to regulatory agencies (e.g., FDA). He has this experience across the spectrum of pharmaceutical/biotech, entrepreneurship, and large CRO businesses.In addition, Dr. Kamauu trained as a medical intern at Hurley Medical Center, where he treated patients in a variety of clinical settings, including Radiology, Emergency Medicine, Internal Medicine, Intensive Care and Cardiology. Dr. Kamauu is a member of leading medical societies where he has presented innovative research in clinical research informatics, public health informatics, and radiology/imaging informatics.
Session Abstract – PMWC 2023 Silicon Valley
Track 2 - January 26 9.00 A.M.-4.30 P.M.
Track Chair:
- Courtney McFall, UCSF
- Ben Rubin, UCSF
Patient-centric data – Real-World Evidence (RWE) and Real-World Data (RWD) - is becoming instrumental in the drug development process and for health care decisions in general. This data is not only informative for the process from discovery to new indications, clinical trial design, and drug development, it also can be of value to monitor post-marketing drug safety and for decision support in clinical practice. As the data becomes a decision driver, science companies and medical organizations are increasingly focused on leveraging RWD and RWE to not only better understand the patient populations using their drugs and the respective outcomes, but also to accelerate clinical decision support. This session will focus on the various aspects of integrating RWE and RWD to support drug development and clinical decision support.
Sessions:
- Clinical Studies Using RWD (PANEL)
Chair: Aaron Kamauu, Navidence
- Liora Schultz, Stanford
- Scott Morris, Optum Life Sciencess
- Sanket Dhurva, UCSF
- Motiur Rahman, FDA
- Farid Vij, Invitae - Beyond the EHR: Acquisition of RWD Types to Enable Precision Medicine (PANEL)
Chair: Riley Bove, UCSF
- Anna Berry, Sypase
- Matthew Lungren, Microsoft
- Ashley Brenton, Optum
- Vasu Chandrasekaran, Ontada - Data Linkage, Harmonization, and Quality (PANEL)
Chair: Vivek Rudrapatna, UCSF
- Rohit Vashisht, UCSF
- Adam Asare, QLHC
- Dan Riskin, Verantos
- Wanmei Ou, Ontada
- Mindy DeRouen, UCSF
- Using RWE to Uncover and Address Health Disparities (PANEL)
Chair: Chris Boone, AbbVie
- Robert Hiatt, UCSF
- Abasi Ene-Obong, 54gene
- Alice Popejoy, UC Davis Health
- Nuray Yurt, Novartis Oncology
- Vic Spain, Genentech - FDA RWD/RWE Draft and Final Guidances
- Motiur Rahman, FDA
- Fireside Chat:
- Vivek Rudrapatna, UCSF
- Hilary Marston, FDA
- Atul Butte, UCSF - From Real World to Regulatory-Grade: Navigating the Evidence Chasm
Chair: Sheila Walcoff, Goldbug Strategies
- Elaine Katrivanos, Tempus
- Kathy Hibbs, 23andMe
- Mike Ryan, McDermott Will & Emery
- Terry Myerson, Truveta
